Verrica Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results, Announced Senior Leadership Changes, and Is Exploring Strategies to Strengthen Its Balance Sheet. Additionally, RBC Capital...
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results, Announced Senior Leadership Changes, and Is Exploring Strategies to Strengthen Its Balance Sheet. Additionally, RBC Capital...
verrica製藥股價下跌，公司報告第三季度財務業績差於預期，宣佈高層領導變更，並正在探索加強資產負債表的戰略。此外，RBC資本...
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results, Announced Senior Leadership Changes, and Is Exploring Strategies to Strengthen Its Balance Sheet. Additionally, RBC Capital Downgraded the Stock From Outperform to Sector Perform and Cut Its Price Target From $11 to $2.
verrica製藥股價下跌，公司公佈Q3業績差於預期，宣佈高級管理層變動，並正探索加強資產負債表的策略。此外，RBC資本將其股票評級從表現優異降級至板塊表現，並將其目標股價從11美元降至2美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。